[UnitedHealthCare]’s pharmacy benefit manager OptumRx Inc. flags Novo Nordisk AS’s just-approved oral semaglutide for type 2 diabetes, Rybelsus, and a handful of other novel or improved treatments for chronic conditions as near-term launches with potentially significant economic impacts in its latest Pipeline Insights Report.
The Q3 report, which is the second to be issued by the major PBM, offers a snapshot of potentially high-cost...




